Participant-Reported Symptoms and Their Effect on Long-Term Adherence in the International Breast Cancer Intervention Study I (IBIS I)

Samuel George Smith, Ivana Sestak, Anthony Howell, John Forbes, Jack Cuzick, Samuel George Smith, Ivana Sestak, Anthony Howell, John Forbes, Jack Cuzick

Abstract

Purpose To assess the role of participant-reported symptoms on long-term adherence to preventive therapy in the United Kingdom sample of the International Breast Cancer Intervention Study (IBIS-I). IBIS-I was a randomized controlled trial that investigated the effectiveness of tamoxifen in reducing the risk of breast cancer among women at increased risk of the disease. Participants and Methods Women were randomly assigned to tamoxifen versus placebo (20 mg/day; n = 4,279). After 456 exclusions, 3,823 women were included in this analysis. Adherence (< 4.5 years or ≥ 4.5 years) was calculated using data from six monthly clinical visits. Analyses were adjusted for age, Tyrer-Cuzick risk, smoking, use of hormone replacement therapy, menopausal status, baseline menopausal symptoms, and treatment. Results Overall, 69.7% of women were adherent for at least 4.5 years (tamoxifen: 65.2% v placebo: 74.0%; P < .001). Differences in adherence between treatment arms were observed from 12 months onward (all P < .01) and were largest at 54 months. Dropout rates were highest in the first 12 to 18 months and decreased thereafter. Women reporting nausea/vomiting were less likely to be adherent in both the tamoxifen (odds ratio [OR], 0.57; 95% CI, 0.37 to 0.86; P = .007) and placebo (OR, 0.58; 95% CI, 0.37 to 0.93; P = .023) arms. Headaches were associated with adherence only in the placebo arm (OR, 0.62; 95% CI, 0.42 to 0.91; P = .016), whereas gynecologic symptoms were significant only in the tamoxifen arm (OR, 0.77; 95% CI, 0.62 to 0.97; P = .024). Effect sizes for each symptom on adherence were not significantly different between the treatment groups ( P > .05). In both treatment arms, we observed significant trends for lower adherence with increasing severity for all symptoms ( P < .01) except headaches ( P = .054). Conclusion In the IBIS-I trial, experiencing predefined symptoms in the first 6 months reduced long-term adherence. Effects were similar between treatment arms, suggesting that women were attributing age-related symptoms to preventive therapy. Interventions were required to support symptom management.

Figures

Fig 1.
Fig 1.
CONSORT diagram for medication adherence analysis within International Breast Cancer Intervention I trial.
Fig 2.
Fig 2.
Kaplan-Meier curve for adherence over 4.5 years of follow-up according to treatment arm.
Fig 3.
Fig 3.
Annual hazard rates for nonadherence according to treatment arm.
Fig 4.
Fig 4.
Adherence for 4.5 years according to severity of symptoms.

References

    1. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. : Breast and cervical cancer in 187 countries between 1980 and 2010: A systematic analysis. Lancet 378:1461-1484, 2011
    1. Cancer Research UK: Breast cancer statistics. 2015. .
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. : Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 136:E359-E386, 2015
    1. Weir HK, Thompson TD, Soman A, et al. : The past, present, and future of cancer incidence in the United States: 1975 through 2020. Cancer 121:1827-1837, 2015
    1. DeSantis C, Ma J, Bryan L, et al. : Breast cancer statistics, 2013. CA Cancer J Clin 64:52-62, 2014
    1. Umar A, Dunn BK, Greenwald P: Future directions in cancer prevention. Nat Rev Cancer 12:835-848, 2012
    1. Cuzick J, Sestak I, Bonanni B, et al. : Selective oestrogen receptor modulators in prevention of breast cancer: An updated meta-analysis of individual participant data. Lancet 381:1827-1834, 2013
    1. Cuzick J, Sestak I, Cawthorn S, et al. : Tamoxifen for prevention of breast cancer: Extended long-term follow-up of the IBIS-I breast cancer prevention trial. Lancet Oncol 16:67-75, 2015
    1. Smith SG, Sestak I, Forster A, et al. : Factors affecting uptake and adherence to breast cancer chemoprevention: A systematic review and meta-analysis. Ann Oncol 27:575-590, 2016
    1. Bober SL, Hoke LA, Duda RB, et al. : Decision-making about tamoxifen in women at high risk for breast cancer: Clinical and psychological factors. J Clin Oncol 22:4951-4957, 2004
    1. Yeomans-Kinney A, Vernon SW, Frankowski RF, et al. : Factors related to enrollment in the breast cancer prevention trial at a comprehensive cancer center during the first year of recruitment. Cancer 76:46-56, 1995
    1. Altschuler A, Somkin CP: Women’s decision making about whether or not to use breast cancer chemoprevention. Women Health 41:81-95, 2005
    1. Donnelly LS, Evans DG, Wiseman J, et al. : Uptake of tamoxifen in consecutive premenopausal women under surveillance in a high-risk breast cancer clinic. Br J Cancer 110:1681-1687, 2014
    1. Heisey R, Pimlott N, Clemons M, et al. : Women’s views on chemoprevention of breast cancer: Qualitative study. Can Fam Physician 52:624-625, 2006
    1. Vogel VG, Costantino JP, Wickerham DL, et al. : Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: Preventing breast cancer. Cancer Prev Res (Phila) 3:696-706, 2010
    1. Powles TJ, Jones AL, Ashley SE, et al. : The Royal Marsden Hospital pilot tamoxifen chemoprevention trial. Breast Cancer Res Treat 31:73-82, 1994
    1. Land SR, Walcott FL, Liu Q, et al. : Symptoms and QOL as predictors of chemoprevention adherence in NRG Oncology/NSABP Trial P-1. J Natl Cancer Inst 108:djv365, 2015
    1. Fallowfield L, Fleissig A, Edwards R, et al. : Tamoxifen for the prevention of breast cancer: Psychosocial impact on women participating in two randomized controlled trials. J Clin Oncol 19:1885-1892, 2001
    1. Land SR, Wickerham DL, Costantino JP, et al. : Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: The NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 295:2742-2751, 2006
    1. Palva T, Ranta H, Koivisto AM, et al. : A double-blind placebo-controlled study to evaluate endometrial safety and gynaecological symptoms in women treated for up to 5 years with tamoxifen or placebo: A substudy for IBIS I Breast Cancer Prevention Trial. Eur J Cancer 49:45-51, 2013
    1. Powles TJ, Hardy JR, Ashley SE, et al. : A pilot trial to evaluate the acute toxicity and feasibility of tamoxifen for prevention of breast cancer. Br J Cancer 60:126-131, 1989
    1. Powles T, Eeles R, Ashley S, et al. : Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial. Lancet 352:98-101, 1998
    1. Razzaboni E, Toss A, Cortesi L, et al. : Acceptability and adherence in a chemoprevention trial among women at increased risk for breast cancer attending the Modena Familial Breast and Ovarian Cancer Center (Italy). Breast J 19:10-21, 2013
    1. Sestak I, Kealy R, Edwards R, et al. : Influence of hormone replacement therapy on tamoxifen-induced vasomotor symptoms. J Clin Oncol 24:3991-3996, 2006
    1. Cuzick J, Forbes J, Edwards R, et al. : First results from the International Breast Cancer Intervention Study (IBIS-I): A randomised prevention trial. Lancet 360:817-824, 2002
    1. Vrijens B, De Geest S, Hughes DA, et al. : A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73:691-705, 2012
    1. Kaplan EL, Meier P: Nonparametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
    1. Colloca L, Miller FG: The nocebo effect and its relevance for clinical practice. Psychosom Med 73:598-603, 2011
    1. Rief W, Avorn J, Barsky AJ: Medication-attributed adverse effects in placebo groups: Implications for assessment of adverse effects. Arch Intern Med 166:155-160, 2006
    1. Rief W, Nestoriuc Y, von Lilienfeld-Toal A, et al. : Differences in adverse effect reporting in placebo groups in SSRI and tricyclic antidepressant trials: A systematic review and meta-analysis. Drug Saf 32:1041-1056, 2009
    1. Amanzio M, Corazzini LL, Vase L, et al. : A systematic review of adverse events in placebo groups of anti-migraine clinical trials. Pain 146:261-269, 2009
    1. Cuzick J, Sestak I, Forbes JF, et al. : Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II): An international, double-blind, randomised placebo-controlled trial. Lancet 383:1041-1048, 2014
    1. Tan K, Petrie KJ, Faasse K, et al. : Unhelpful information about adverse drug reactions. BMJ 349:g5019, 2014
    1. Ammassari A, Murri R, Pezzotti P, et al. : Self-reported symptoms and medication side effects influence adherence to highly active antiretroviral therapy in persons with HIV infection. J Acquir Immune Defic Syndr 28:445-449, 2001
    1. Heller MK, Chapman SCE, Horne R: Beliefs about medication predict the misattribution of a common symptom as a medication side effect: Evidence from an analogue online study. J Psychosom Res 79:519-529, 2015
    1. von Blanckenburg P, Schuricht F, Albert US, et al. : Optimizing expectations to prevent side effects and enhance quality of life in breast cancer patients undergoing endocrine therapy: Study protocol of a randomized controlled trial. BMC Cancer 13:426, 2013
    1. Sohl SJ, Schnur JB, Montgomery GH: A meta-analysis of the relationship between response expectancies and cancer treatment-related side effects. J Pain Symptom Manage 38:775-784, 2009
    1. Nestoriuc Y, von Blanckenburg P, Schuricht F, et al. : Is it best to expect the worst? Influence of patients’ side-effect expectations on endocrine treatment outcome in a 2-year prospective clinical cohort study. Ann Oncol 27:1909-1915, 2016
    1. Mann E, Smith MJ, Hellier J, et al. : Cognitive behavioural treatment for women who have menopausal symptoms after breast cancer treatment (MENOS 1): A randomised controlled trial. Lancet Oncol 13:309-318, 2012
    1. van Vulpen JK, Peeters PH, Velthuis MJ, et al. : Effects of physical exercise during adjuvant breast cancer treatment on physical and psychosocial dimensions of cancer-related fatigue: A meta-analysis. Maturitas 85:104-111, 2016
    1. Irwin ML, Cartmel B, Gross CP, et al. : Randomized exercise trial of aromatase inhibitor-induced arthralgia in breast cancer survivors. J Clin Oncol 33:1104-1111, 2015
    1. Duijts SFA, van Beurden M, Oldenburg HS, et al. : Efficacy of cognitive behavioral therapy and physical exercise in alleviating treatment-induced menopausal symptoms in patients with breast cancer: results of a randomized, controlled, multicenter trial. J Clin Oncol 30:4124-4133, 2012
    1. Roetzheim RG, Lee JH, Fulp W, et al. : Acceptance and adherence to chemoprevention among women at increased risk of breast cancer. Breast 24:51-56, 2015

Source: PubMed

Sponsorer og samarbeidspartnere

Medisinsk tilstand

Legemiddelintervensjoner

3
Abonnere